Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Retrophin, Inc. (NASDAQ: RTRX).

Full DD Report for RTRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: RTRX)

Retrophin to Present at the Jefferies 2018 London Healthcare Conference
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 4:40 p.m. GMT (11:40 a.m. ET). A liv...
Source: GlobeNewswire
Date: November, 07 2018 16:30
Retrophin, Inc. (RTRX) CEO Steve Aselage on Q3 2018 Results - Earnings Call Transcript
Retrophin, Inc. (RTRX) Q3 2018 Earnings Conference Call November 01, 2018 04:30 PM ET Executives Chris Cline - VP, IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Dr. Noah Rosenberg - CMO Dr. Bill Rote - SVP, R&D Analysts Joseph Schwartz - Leerink ...
Source: SeekingAlpha
Date: November, 01 2018 21:30
Retrophin misses by $0.40, misses on revenue
Retrophin (NASDAQ: RTRX ): Q3 Non-GAAP EPS of -$0.68 misses by $0.40 ; GAAP EPS of -$1.34 misses by $0.86 . More news on: Retrophin, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 16:05
Retrophin Reports Third Quarter 2018 Financial Results
Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million convertible senior notes due 2025 SAN DIEGO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Retroph...
Source: GlobeNewswire
Date: November, 01 2018 16:01
Robbins Arroyo LLP Is Investigating the Officers and Directors of Retrophin, Inc. (RTRX) on Behalf of Shareholders
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Retrophin, Inc. (NASDAQ: RTRX) breached their fiduciary duties to shareholders. Retrophin is a biopharmaceutical company that focuses on the development and commercialization of therap...
Source: Business Wire
Date: October, 29 2018 20:44
Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018 SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Journal of the American Society of Nephrology (JASN) has published online (doi: 10.1681/ASN.201...
Source: GlobeNewswire
Date: October, 25 2018 16:01
Key events next week - healthcare
Noteworthy events during the week of October 21 - 27 for healthcare investors. More news on: Alpine Immune Sciences, Inc., NovoCure, ViewRay, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 19 2018 11:08
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Axovant Sciences Ltd....
Source: GlobeNewswire
Date: October, 19 2018 09:10
Retrophin to Report Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2018 financial results on Thursday, November 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the fin...
Source: GlobeNewswire
Date: October, 18 2018 16:30
Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
SAN DIEGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018. The Company wil...
Source: GlobeNewswire
Date: October, 05 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0828.7529.0929.4528.10644,889
2018-05-2128.3228.2428.57927.92234,565
2018-05-1827.2728.1828.3526.8213435,515
2018-05-1726.9227.2727.4726.48244,245
2018-05-1626.6326.8827.0026.51444,812

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1424,64245,06554.6810Short
2018-12-1318,12638,73546.7949Short
2018-12-1229,27686,04934.0225Cover
2018-12-1121,49139,76854.0409Short
2018-12-1026,413115,35922.8963Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RTRX.


About Retrophin, Inc. (NASDAQ: RTRX)

Logo for Retrophin, Inc. (NASDAQ: RTRX)

Retrophin, Inc. OTCQB: RTRX New York based, biotechnology company focused on discovering and developing treatments for rare and life threatening diseases. Retrophin is currently developing treatments for Focal Segmental Glomerulosclerosis FSGS , Pantothenate Kinase Associated Neurodegeneration PKAN , Duchenne Muscular Dystrophy DMD , and Spinal Muscular Atrophy SMA .

 

Contact Information

 

 

Current Management

  • Martin Shkreli / CEO, Founder
  • Marc Panoff / CFO, Chief Accounting Officer
  • Marek Biestek / VP, Fin.
  • Michael Smith / IR
  • Tom Fernandez / IR
  • Stephen Aselage /
  • Steve Richardson /
  • Martin Shkreli /

Current Share Structure

  • Market Cap: $1,051,325,027 - 05/11/2018
  • Authorized: 100,000,000 - 03/05/2013
  • Issue and Outstanding: 39,943,960 - 04/30/2018
  • Float: 8,280,000 - 03/05/2013

 


Recent Filings from (NASDAQ: RTRX)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 05 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018

 

 


Daily Technical Chart for (NASDAQ: RTRX)

Daily Technical Chart for (NASDAQ: RTRX)


Stay tuned for daily updates and more on (NASDAQ: RTRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RTRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RTRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RTRX and does not buy, sell, or trade any shares of RTRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/